RESOURCES
Lilly's weight-loss drug cuts diabetes risk in overweight patients
Manas Mishra, Reuters
August 20, 202410:25 AM CDT
​​
Eli Lilly's (LLY.N) weight-loss drug, Zepbound, drastically cut the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the drugmaker said on Tuesday.​ In a trial involving 1,032 adults, patients who were on weekly injections showed a 94% reduction in the risk of progression to type 2 diabetes, compared with placebo, Lilly reported in a statement.​"We just don't see numbers like this in metabolic space," BMO Capital Markets analyst Evan Seigerman said. He added that Novo's drug had also showed a 73% risk reduction after three years in a separate late-stage trial.
​
Tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says
Katherine Dillinger, CNN
Tue August 20, 2024
​
A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight used it weekly, it lowered their risk of progression to diabetes by 94% compared with a placebo, according to drugmaker Eli Lilly.
​